{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-167481","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2024-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.331453+00:00","generated_at":"2026-06-01T02:12:40.880928+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Wave Life Sciences reports 46% mHTT lowering in HD trial; allele-selective silencing demonstrated","bullets":["SELECT-HD: 30 mg WVE-003 Q8W showed 46% mean mHTT reduction vs placebo at 24 weeks (p=0.0007); 44% at 28 weeks (p=0.0002).","Wild-type HTT preserved; allele-selective silencing confirmed.","mHTT reduction correlated with slowing of caudate atrophy (R=-0.50, p=0.047), an imaging biomarker predictive of clinical outcomes.","Generally safe and well-tolerated; no serious adverse events reported.","Cash runway into Q4 2025; Wave to discuss accelerated approval path with regulators."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-167481","json":"https://secwatch.observer/filing/0001193125-24-167481.json","markdown":"https://secwatch.observer/filing/0001193125-24-167481.md","text":"https://secwatch.observer/filing/0001193125-24-167481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524167481/0001193125-24-167481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524167481/d771392d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:12:40.880928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}